Repurposing High-Throughput Screening Reveals Unconventional Drugs with Antimicrobial and Antibiofilm Potential Against Methicillin-Resistant Staphylococcus aureus from a Cystic Fibrosis Patient DOI Creative Commons
Arianna Pompilio,

Veronica Lupetti,

Valentina Puca

et al.

Antibiotics, Journal Year: 2025, Volume and Issue: 14(4), P. 402 - 402

Published: April 14, 2025

Background/Objectives: Antibiotic therapy faces challenges from rising acquired and biofilm-related antibiotic resistance rates. High levels to commonly used antibiotics have been observed in methicillin-resistant Staphylococcus aureus (MRSA) strains among cystic fibrosis (CF) patients, indicating an urgent need for new antibacterial agents. This study aimed identify potential novel therapeutics with antibiofilm activities against MRSA CF strain by screening, the first time, Drug Repurposing Compound Library (MedChem Express). Methods/Results: Among 3386 compounds, a high-throughput screening-based spectrophotometric approach identified 2439 (72%), 654 (19.3%), 426 (12.6%) drugs active planktonic cells, biofilm formation, preformed biofilm, respectively, although different extents. The most hits were 193 (5.7%), causing 100% growth inhibition; 5 (0.14%), excellent activity formation (i.e., reduction ≥ 90%); 4, showing high 60% ≤ < 90%) biofilms. belonged several primary research areas, “cancer” being prevalent. After performing literature review other, already published biological properties that could be relevant lung environment other pathogens, anti-inflammatory anti-virulence potential), interesting following: 5-(N,N-Hexamethylene)-amiloride (diuretic), Toremifene (anticancer), Zafirlukast (antiasthmatic), Fenretide Montelukast (antiasthmatic) S. cells; Hemin formation; Heparin, Clemastine (antihistaminic), Bromfenac (nonsteroidal anti-inflammatory) established Conclusions: These findings warrant further vitro vivo studies confirm of repurposing these compounds managing infections caused patients.

Language: Английский

Repurposing High-Throughput Screening Reveals Unconventional Drugs with Antimicrobial and Antibiofilm Potential Against Methicillin-Resistant Staphylococcus aureus from a Cystic Fibrosis Patient DOI Creative Commons
Arianna Pompilio,

Veronica Lupetti,

Valentina Puca

et al.

Antibiotics, Journal Year: 2025, Volume and Issue: 14(4), P. 402 - 402

Published: April 14, 2025

Background/Objectives: Antibiotic therapy faces challenges from rising acquired and biofilm-related antibiotic resistance rates. High levels to commonly used antibiotics have been observed in methicillin-resistant Staphylococcus aureus (MRSA) strains among cystic fibrosis (CF) patients, indicating an urgent need for new antibacterial agents. This study aimed identify potential novel therapeutics with antibiofilm activities against MRSA CF strain by screening, the first time, Drug Repurposing Compound Library (MedChem Express). Methods/Results: Among 3386 compounds, a high-throughput screening-based spectrophotometric approach identified 2439 (72%), 654 (19.3%), 426 (12.6%) drugs active planktonic cells, biofilm formation, preformed biofilm, respectively, although different extents. The most hits were 193 (5.7%), causing 100% growth inhibition; 5 (0.14%), excellent activity formation (i.e., reduction ≥ 90%); 4, showing high 60% ≤ < 90%) biofilms. belonged several primary research areas, “cancer” being prevalent. After performing literature review other, already published biological properties that could be relevant lung environment other pathogens, anti-inflammatory anti-virulence potential), interesting following: 5-(N,N-Hexamethylene)-amiloride (diuretic), Toremifene (anticancer), Zafirlukast (antiasthmatic), Fenretide Montelukast (antiasthmatic) S. cells; Hemin formation; Heparin, Clemastine (antihistaminic), Bromfenac (nonsteroidal anti-inflammatory) established Conclusions: These findings warrant further vitro vivo studies confirm of repurposing these compounds managing infections caused patients.

Language: Английский

Citations

0